Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Raises $15M in Private Funding

NEW YORK (GenomeWeb News) – Quanterix, a privately held firm developing a single molecule array technology, said today that it has closed a second tranche of its Series A financing round, bringing in a total of $15 million.
The Cambridge, Mass.-based firm said that proceeds from the round of financing would be used to validate its platform and accelerate development of ultrasensitive assays targeting a variety of biological analytes. Quanterix said that it is developing the single molecule array (SiMoA) technology for clinical diagnostic, drug development, and life science research applications.
The company was founded last year by David Walt, a professor at Tufts University, and Nicholas Naclerio, a life sciences industry veteran, who previously served as president of ParAllele BioScience and led the commercial launch several years ago of Motorola’s CodeLink microarray platform. Naclerio, who is serving as chairman and interim CEO of Quanterix, also was on the board of privately held True Materials, which was recently acquired by Affymetrix.
Quanterix holds an exclusive license to an intellectual property portfolio covering the SiMoA technology from Walt’s laboratory at Tufts.
Investors in the round included Arch Venture Partners, Bain Capital Ventures, and Flagship Ventures.
“We see tremendous value and promise for this technology,” Keith Crandell, a member of Quanterix’s board and a co-founder and managing director of Arch Venture Partners, said in a statement. “The ability to quantify biomarkers present at low concentrations in blood could provide critical information to clinicians and help guide health care decisions.”
Quanterix is currently developing protein biomarker-based assays for cancer, chronic inflammatory disease, and cardiovascular disease.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.